Published in Microbiology on May 01, 2007
Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol (2007) 1.39
Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol (2008) 0.96
Source tracking Mycobacterium ulcerans infections in the Ashanti region, Ghana. PLoS Negl Trop Dis (2015) 0.90
Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans. J Clin Microbiol (2009) 0.86
Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol (2009) 0.83
Clinical, microbiological and pathological findings of Mycobacterium ulcerans infection in three Australian Possum species. PLoS Negl Trop Dis (2014) 0.82
Genotyping Tools for Mycobacterium ulcerans-Drawbacks and Future Prospects. Mycobact Dis (2014) 0.77
Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ (2005) 11.02
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis (2005) 3.25
Human health benefits from livestock vaccination for brucellosis: case study. Bull World Health Organ (2004) 2.90
A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem (2003) 2.84
Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis (2002) 2.40
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis (2012) 2.13
Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol (2006) 2.10
Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis (2012) 1.95
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis (2011) 1.81
Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis (2013) 1.72
Use of disability adjusted life years in the estimation of the disease burden of echinococcosis for a high endemic region of the Tibetan plateau. Am J Trop Med Hyg (2004) 1.70
Synthetic GPI array to study antitoxic malaria response. Nat Chem Biol (2008) 1.67
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med (2007) 1.56
Zoonotic Mycobacterium bovis-induced tuberculosis in humans. Emerg Infect Dis (2013) 1.53
Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis (2011) 1.51
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One (2008) 1.51
Stray dog population demographics in Jodhpur, India following a population control/rabies vaccination program. Prev Vet Med (2010) 1.51
Evaluation of the discriminatory power of variable number tandem repeat (VNTR) typing of Mycobacterium bovis strains. Vet Microbiol (2005) 1.45
Representative seroprevalences of brucellosis in humans and livestock in Kyrgyzstan. Ecohealth (2011) 1.44
Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med Int Health (2008) 1.44
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis (2008) 1.43
Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis (2013) 1.42
Synergy between public health and veterinary services to deliver human and animal health interventions in rural low income settings. BMJ (2005) 1.41
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol (2007) 1.39
Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis (2010) 1.37
Human and animal vaccination delivery to remote nomadic families, Chad. Emerg Infect Dis (2007) 1.37
Evaluation of decontamination methods and growth media for primary isolation of Mycobacterium ulcerans from surgical specimens. J Clin Microbiol (2004) 1.36
Rabies diagnosis for developing countries. PLoS Negl Trop Dis (2008) 1.36
Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans. Chem Commun (Camb) (2003) 1.33
Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog (2009) 1.33
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep (2008) 1.32
Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One (2011) 1.31
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase. Chembiochem (2005) 1.27
Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol (2008) 1.27
Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol (2006) 1.26
Owner valuation of rabies vaccination of dogs, Chad. Emerg Infect Dis (2008) 1.24
Domestic dog demographic structure and dynamics relevant to rabies control planning in urban areas in Africa: the case of Iringa, Tanzania. BMC Vet Res (2012) 1.23
Structure elucidation of a novel family of mycolactone toxins from the frog pathogen Mycobacterium sp. MU128FXT by mass spectrometry. Chem Commun (Camb) (2005) 1.21
Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis (2002) 1.20
Antibiotic susceptibility and molecular diversity of Bacillus anthracis strains in Chad: detection of a new phylogenetic subgroup. J Clin Microbiol (2006) 1.20
Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun (2003) 1.20
Anti-carbohydrate antibodies for the detection of anthrax spores. Angew Chem Int Ed Engl (2006) 1.19
Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther (2009) 1.18
Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol (2006) 1.18
Mycobacterium bovis isolates from tuberculous lesions in Chadian zebu carcasses. Emerg Infect Dis (2006) 1.17
Risk factors for Entamoeba histolytica infection in an agricultural community in Hanam province, Vietnam. Parasit Vectors (2011) 1.16
Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis (2007) 1.16
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine (2002) 1.16
Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis (2007) 1.16
A one health framework for estimating the economic costs of zoonotic diseases on society. Ecohealth (2012) 1.15
Combining PCR with microscopy to reduce costs of laboratory diagnosis of Buruli ulcer. Am J Trop Med Hyg (2011) 1.15
Ascaris lumbricoides and Trichuris trichiura infections associated with wastewater and human excreta use in agriculture in Vietnam. Parasitol Int (2013) 1.13
Zoonotic transmission of tuberculosis between pastoralists and their livestock in South-East Ethiopia. Ecohealth (2012) 1.13
Molecular characterization and drug resistance testing of Mycobacterium tuberculosis isolates from Chad. J Clin Microbiol (2006) 1.12
Molecular characterization of Mycobacterium bovis strains isolated from cattle slaughtered at two abattoirs in Algeria. BMC Vet Res (2009) 1.11
Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health (2005) 1.11
Use of diagnostic microarrays for determination of virulence gene patterns of Escherichia coli K1, a major cause of neonatal meningitis. J Clin Microbiol (2005) 1.10
Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis (2013) 1.10
Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol (2006) 1.08
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa. J Bacteriol (2010) 1.08
Improving environmental sanitation, health, and well-being: a conceptual framework for integral interventions. Ecohealth (2009) 1.06
The genome, evolution and diversity of Mycobacterium ulcerans. Infect Genet Evol (2012) 1.06
The N'-terminal domain of glyceraldehyde-3-phosphate dehydrogenase of the apicomplexan Plasmodium falciparum mediates GTPase Rab2-dependent recruitment to membranes. Biol Chem (2003) 1.05
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One (2007) 1.04
Risk factors of bovine tuberculosis in cattle in rural livestock production systems of Ethiopia. Prev Vet Med (2009) 1.04
Molecular characterisation of Mycobacterium bovis isolated from cattle slaughtered at the Bamako abattoir in Mali. BMC Vet Res (2008) 1.03
A novel mycolactone toxin obtained by biosynthetic engineering. Chembiochem (2007) 1.02
African 1, an epidemiologically important clonal complex of Mycobacterium bovis dominant in Mali, Nigeria, Cameroon, and Chad. J Bacteriol (2009) 1.02
Research in a war zone. Nature (2011) 1.02
Molecular epidemiology and antibiotic susceptibility of livestock Brucella melitensis isolates from Naryn Oblast, Kyrgyzstan. PLoS Negl Trop Dis (2013) 1.02
Mainstreaming one health. Ecohealth (2012) 1.01
Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue? PLoS Negl Trop Dis (2011) 1.01
Demographic and health surveillance of mobile pastoralists in Chad: integration of biometric fingerprint identification into a geographical information system. Geospat Health (2008) 1.00
Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis (2009) 1.00
Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol (2009) 1.00
Prevalence of bovine tuberculosis in pastoral cattle herds in the Oromia region, southern Ethiopia. Trop Anim Health Prod (2011) 0.99
Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One (2011) 0.99
Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol (2006) 0.99
Quantification of diarrhea risk related to wastewater contact in Thailand. Ecohealth (2012) 0.99
European 1: a globally important clonal complex of Mycobacterium bovis. Infect Genet Evol (2011) 0.98
Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis (2012) 0.98
Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis (2008) 0.96
Correction: Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis (2015) 0.96
Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol (2008) 0.96
Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem (2012) 0.96
Anthrax spore detection by a luminex assay based on monoclonal antibodies that recognize anthrose-containing oligosaccharides. Clin Vaccine Immunol (2010) 0.96